The net proceeds from the IPO, along with NextCure's cash on hand, will largely be used to drive its lead product, NC318, through clinical trials and testing.
SUBSCRIBE
Biohealth Innovation
Founding Member of
Biohealth Innovation
The net proceeds from the IPO, along with NextCure's cash on hand, will largely be used to drive its lead product, NC318, through clinical trials and testing.